Regulation of NUB1 Activity through Non-Proteolytic Mdm2-Mediated Ubiquitination

PLoS One. 2017 Jan 18;12(1):e0169988. doi: 10.1371/journal.pone.0169988. eCollection 2017.

Abstract

NUB1 (Nedd8 ultimate buster 1) is an adaptor protein which negatively regulates the ubiquitin-like protein Nedd8 as well as neddylated proteins levels through proteasomal degradation. However, molecular mechanisms underlying this function are not completely understood. Here, we report that the oncogenic E3 ubiquitin ligase Mdm2 is a new NUB1 interacting protein which induces its ubiquitination. Interestingly, we found that Mdm2-mediated ubiquitination of NUB1 is not a proteolytic signal. Instead of promoting the conjugation of polyubiquitin chains and the subsequent proteasomal degradation of NUB1, Mdm2 rather induces its di-ubiquitination on lysine 159. Importantly, mutation of lysine 159 into arginine inhibits NUB1 activity by impairing its negative regulation of Nedd8 and of neddylated proteins. We conclude that Mdm2 acts as a positive regulator of NUB1 function, by modulating NUB1 ubiquitination on lysine 159.

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • HEK293 Cells
  • Humans
  • Huntingtin Protein / genetics
  • Huntingtin Protein / metabolism
  • Lysine / metabolism
  • NEDD8 Protein
  • Proto-Oncogene Proteins c-mdm2 / genetics
  • Proto-Oncogene Proteins c-mdm2 / metabolism*
  • Transcription Factors / genetics
  • Transcription Factors / metabolism*
  • Ubiquitination
  • Ubiquitins / genetics
  • Ubiquitins / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • HTT protein, human
  • Huntingtin Protein
  • NEDD8 Protein
  • NEDD8 protein, human
  • NUB1 protein, human
  • Transcription Factors
  • Ubiquitins
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • Lysine

Grants and funding

This work was supported by grants from INSERM, INCA, and La Ligue Contre le Cancer. TB was supported by a fellowship from La Ligue contre le Cancer and INSERM. EB was supported by Canceropôle PACA. The Marseille Proteomic facility (MaP; http://map.univmed.fr/) is supported by IBiSA (Infrastructures Biologie Santé et Agronomie), Canceropôle PACA, Région PACA and Institut Paoli-Calmettes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.